Will Date

1 month ago | vascularspecialistonline.com | Will Date

Merit Medical Systems has announced that the six-month results from the randomized arm of the Wrapsody arteriovenous access efficacy—WAVE—trial are scheduled for publication in the April issue of Kidney International, ahead of the presentation of 12-month results from the trial at the Society of Interventional Radiology’s 50th annual scientific meeting (March 29–April 2) in Nashville, Tennessee.

1 month ago | vascularspecialistonline.com | Will Date

Stereotaxis has announced a Food and Drug Administration (FDA) regulatory submission for the first robotically navigated catheter designed to expand usage of robotic magnetic navigation into the broader endovascular field. Emagin 5F is the first in a family of robotically navigated endovascular devices being developed by Stereotaxis. The Emagin brand—short for Endovascular Magnetic Intervention—will encompass a portfolio of robotic catheters and wires.

Jul 17, 2024 | vascularspecialistonline.com | Will Date |Bryan Kay

Humacyte recently announced it has been granted Regenerative Medicine Advanced Therapy (RMAT) designation from the US Food and Drug Administration (FDA) for its investigational acellular tissue-engineered vessel (ATEV), designed to treat patients with advanced peripheral arterial disease (PAD).

Jun 24, 2024 | vascularnews.com | Will Date

The US Food and Drug Administration (FDA)-approved Gore Excluder Thoracoabdominal Branch Endoprosthesis (TAMBE) has been shown to be safe and effective at 30 days for the treatment of patients with complex aortic aneurysms involving the visceral aorta. This is according to findings of the TAMBE trial, a prospective non-randomized multicenter study investigating the use of the TAMBE device in thoracoabdominal and pararenal aortic patients, enrolled in the U.S. and Europe.

Jun 19, 2024 | vascularspecialistonline.com | Will Date

If you had cancer you would go to a cancer center where you would get a multidisciplinary approach,” SVS President Joseph Mills, MD, tells VS@VAM, drawing on this example to highlight the importance of multidisciplinary teams for amputation prevention in patients with diabetes and peripheral arterial disease (PAD)—something, he says, is currently lacking in many centers.